New and emerging strategies for reducing cardiometabolic risk factors (Q36459419)

14 August 2017

1 reference

title

New and emerging strategies for reducing cardiometabolic risk factors (English)

1 reference

14 August 2017

Philip T Rodgers

1

1 reference

PubMed ID

16637783

14 August 2017

Dawn C Fuke

series ordinal

2

1 reference

PubMed ID

16637783

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

14 August 2017

1 reference

14 August 2017

26

1 reference

14 August 2017

5 Pt 2

1 reference

14 August 2017

13S-31S; quiz 43S-45S

1 reference

Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians

14 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Rimonabant--a selective CB1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Increasing HDL Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Torcetrapib and atorvastatin--should marketing drive the research agenda?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Selling safety--lessons from muraglitazar

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Amylin agonists: a novel approach in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Overview of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Ramipril and the development of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Safety of telmisartan in patients with arterial hypertension : an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Possible beneficial effect of telmisartan on glycemic control in diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor antagonist and ACE inhibitor therapy: observations from Val-HeFT and CALM

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.5PART2.13S

10.1592/PHCO.26.5PART2.13S

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16637783